Captiva Teams with FCG to Target Life Science Market; FCG Bundling InputAccel with FirstDoc ECM Solution to Reduce Clinical Trial Discovery Times.

Business Editors/High-Tech Writers

SAN DIEGO--(BUSINESS WIRE)--May 25, 2004

Captiva Software Corp. (NASDAQ:CPTV), a leading provider of input management solutions, today announced a value-added reseller agreement with First Consulting Group Inc. (FCG) (NASDAQ:FCGI), a leading provider of outsourcing, consulting, technology and systems implementation and integration to health-related industries. Through the agreement, FCG will bundle InputAccel(R), Captiva's flagship document capture solution, with FirstDoc(TM) Clinical Trials, part of FCG's new enterprise content management (ECM) solution suite. Built on a Documentum platform, FirstDoc Clinical Trials offers life science and clinical research organizations (CROs) a single foundation to manage information, documentation and workflow. The agreement is projected to eventually result in at least $500,000 in revenue to Captiva annually.

"We're pleased to integrate InputAccel as the document capture platform of choice within FirstDoc Clinical Trials, as it provides the robust capture capability, flexibility and scalability our customers demand," said Mark Vermette, director of Clinical Solutions for FCG's Life Sciences practice. "We developed FirstDoc Clinical Trials to streamline and sharply reduce clinical trial document cycle times by as much as two-thirds, which is consistent with estimates life science analysts have projected for companies that leverage advanced clinical automation tools. We believe our solution addresses a need that has yet to be adequately addressed by the IT vendor marketplace."

According to Gartner Group, research and development remains the largest realm of IT spending within the pharmaceutical and CRO industries, estimated at $13.2 billion in 2002. It asserts that very little of the investment so far has addressed these companies' clinical documentation and data management challenges. Its findings show that 95% of clinical trial information is paper-based, which results in clinical trial managers making slow and sometimes inaccurate decisions based on old data.

"We're pleased that FCG has elected to include InputAccel as a key technology within its clinical trial management suite, which offers a compelling value proposition and addresses a real pain point in the CRO marketplace. We look forward to working closely with the FCG Life Sciences group, as it has been quite successful in establishing a leadership position in serving these customers," said Howard Dratler, Captiva's executive vice president of Field Operations. "This is an excellent opportunity for Captiva to bolster our already-strong presence in the life science realm, as our input management solutions have shown proven ROI for many world-class pharmaceutical companies such as Pfizer, Merck, Monsanto, Roche and many others."

InputAccel is an award-winning document capture system that transforms mission-critical data from paper and faxes into business-ready content. InputAccel ensures the integrity of incoming data and converts it into formats accessible in back-end systems, including XML, image files and custom transaction formats. By delivering accurate, timely and usable data to enterprise systems, InputAccel creates unparalleled efficiencies for the many Global 2000 customers the solution serves.

FCG's FirstDoc Clinical Trials is one of the few solutions tailored to manage clinical documentation and help companies overcome some of the challenging issues inherent in the clinical trials process. FirstDoc Clinical Trials delivers real-time management and status reporting of clinical documents to researchers, prompting fewer errors and faster drug discovery and development.

About FCG

FCG is a leading provider of outsourcing, consulting, systems implementation and integration services for healthcare, pharmaceutical and other life sciences organizations throughout North America, Europe and Asia. Through combinations of on-site, off-site and offshore outsourced services, FCG provides low-cost, high-quality offerings to improve its client's performance. The firm's consulting and integration services increase clients' operations effectiveness with and through information technology, resulting in reduced costs, improved customer service, enhanced quality of patient care and more rapid introduction of new pharmaceutical compounds. For more information about FCG, call 800-345-0957 or visit www.fcg.com.

About Captiva

Captiva Software Corp. (NASDAQ:CPTV) is a leading provider of input management software solutions. Since 1989, the company's award-winning products have been used to manage business critical information from paper, faxed and scanned forms and documents, Internet forms and XML data streams into the enterprise in a more accurate, timely and cost-effective manner. These products automate the processing of billions of forms and documents annually, converting their contents into information that is usable in database, document, content and other information management systems. Captiva's technology serves thousands of users in insurance, financial services, government, business process outsourcing, direct marketing and other markets. For more information, visit www.captivasoftware.com.

InputAccel is a registered trademark of Captiva Software Corp. FirstDoc is a trademark of First Consulting Group Inc. All other trademarks or registered trademarks are the property of their respective owners.

This press release may contain forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they prove incorrect, could cause Captiva's results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, among other things, any projections of earnings, revenues (including where the underlying contract has already been signed), or other financial items; any statements of the plans, strategies, and objectives of management for future operations; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief and any statement of assumptions underlying any of the foregoing. The risks, uncertainties and assumptions referred to above include, among other things, performance of contracts by customers and partners; employee management issues; the timely development, production and acceptance of products and services and their feature sets; the challenge of managing asset levels, including inventory; the flow of products into third-party distribution channels; and the difficulty of keeping expense growth at modest levels while increasing revenues. Announcements of contract awards should not be interpreted as reflecting revenue in any particular period and may relate to revenue recorded in prior periods. These and other risks and factors that could cause events or Captiva's results to differ from those expressed or implied by such forward-looking statements are described in our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. Captiva assumes no obligation and does not intend to update these forward-looking statements.